MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
News headline image
AstraZeneca begins trading on the New York Stock Exchange
From AstraZeneca
Via Business Wire
News headline image
Better Artificial Intelligence Stock: IonQ vs. D-Wave Quantum ↗
Both stocks are speculative, but one may stand out as the less risky choice. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing
LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq... 
Via MarketMinute
Topics Regulatory Compliance
AstraZeneca PLC (NASDAQ:AZN) Emerges as a Quality Investment Candidate ↗
Via Chartmill
AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
Via MarketBeat
Topics ETFs
News headline image
Why Did EBS Stock Fall 13% Today? ↗
New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties. 
Via Stocktwits
Topics Law Enforcement Lawsuit
News headline image
The Newest Stock in the Nasdaq-100 Soared 549,000% Since Its IPO, and It's Still a Buy Right Now, According to Wall Street (Hint: Not Strictly a Tech Company) ↗
Shares of this household name outperformed the broader market indexes in 2025, and that could be more to come. 
Via The Motley Fool
Topics Artificial Intelligence Bankruptcy Initial Public Offering
Records, Subpoenas, and $4,600 Gold ↗
Via Chartmill
Topics Law Enforcement
News headline image
Retail’s Tech Coronation: Walmart Joins the Nasdaq-100 Following Historic Exchange Pivot
In a move that signals the definitive blurring of the lines between traditional retail and big tech, Walmart Inc. (Nasdaq: WMT) is officially scheduled to join the Nasdaq-100 Index prior to the market... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Walmart (WMT) Hits All-Time High as Investors Pivot to Consumer Defensive Giants
Walmart Inc. (NYSE: WMT) reached an unprecedented milestone on Monday, January 12, 2026, with its stock price closing at an all-time high of $117.48. The retail giant’s surge comes amidst a broader... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by... 
Via MarketMinute
News headline image
AMD Ignites the ‘Yotta-Scale’ Era: Unveiling the Instinct MI400 and Helios AI Infrastructure at CES 2026
LAS VEGAS — In a landmark keynote that has redefined the trajectory of high-performance computing, Advanced Micro Devices, Inc. (NASDAQ:AMD) Chair and CEO Dr. Lisa Su took the stage at CES 2026 to... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
From AstraZeneca
Via Business Wire
News headline image
Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge
As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Is IonQ Stock a Buy Now? ↗
This rising star in quantum computing is a high-risk but potentially high-reward play. 
Via The Motley Fool
News headline image
The Motley Fool Interviews MichaelAaron Flicker: Hacking the Human Mind ↗
MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's Best Brands." 
Via The Motley Fool
News headline image
AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗
AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders. 
Via Chartmill
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗
The stocks listed here trade at forward earnings multiples of less than 18. 
Via The Motley Fool
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
News headline image
What to Watch With IonQ Stock in 2026 ↗
The New Year is shaping up to be an important one for this quantum computing stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
From AstraZeneca
Via Business Wire
News headline image
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
From AstraZeneca
Via Business Wire
News headline image
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days. 
Via Stocktwits
Topics World Trade
News headline image
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries. 
Via Stocktwits
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story